SCHEMBL5360968

SCHEMBL5360968

Cc1c(Br)ccc2c1C(=Cc1cc(Br)c(O)c(C(C)(C)C)c1)C(=O)N2

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 3/20 0.54
ERBB2 P04626 3/20 0.54
IGF1R P08069 1/20 0.54
RAF1 P04049 9/20 0.48
LRRK2 Q5S007 3/20 0.48
MAP1LC3B Q9GZQ8 3/20 0.48
PSEN1 P49768 1/20 0.48
PSEN2 P49810 1/20 0.48
APH1B Q8WW43 1/20 0.48
NCSTN Q92542 1/20 0.48
APH1A Q96BI3 1/20 0.48
PSENEN Q9NZ42 1/20 0.48
NTRK1 P04629 1/20 0.48
ARAF P10398 1/20 0.48
PIM1 P11309 1/20 0.48
BRAF P15056 1/20 0.48
CSNK2A1 P68400 1/20 0.48
PIM3 Q86V86 1/20 0.48
SIRT2 Q8IXJ6 1/20 0.48
SIRT1 Q96EB6 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5364049 0.95 ERBB2 (0.59) EGFRERBB2IGF1RRAF1LRRK2
SCHEMBL5367617 0.92 ERBB2 (0.53) EGFRERBB2IGF1RRAF1LRRK2
SCHEMBL5358360 0.87 LRRK2 (0.47) EGFRERBB2IGF1RRAF1LRRK2
SCHEMBL5358709 0.86 MAP1LC3B (0.63) EGFRRAF1LRRK2MAP1LC3BPSEN1
SCHEMBL5362776 0.85 ERBB2 (0.67) EGFRERBB2IGF1RRAF1LRRK2
SCHEMBL5366011 0.84 ERBB2 (0.61) EGFRERBB2IGF1RRAF1LRRK2
SCHEMBL7136800 0.83 MAP1LC3B (0.56) EGFRRAF1LRRK2MAP1LC3BPSEN1
SCHEMBL7137523 0.83 ERBB2 (0.46) EGFRERBB2IGF1RRAF1SIRT2
SCHEMBL5368765 0.83 ERBB2 (0.42) EGFRERBB2IGF1RRAF1LRRK2
SCHEMBL7137544 0.82 LRRK2 (0.49) EGFRRAF1LRRK2MAP1LC3BPSEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7202265-B2 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. (US) 2007-04-10 US disclosed
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. 2005-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease FRK, PTK2, DSTYK EGFR 286/4885ERBB2 19/4885IGF1R 90/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.